Frontier Pharma:胰臟癌症 - First-in-Class的革新認識和商業化
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
|出版日期||內容資訊||英文 88 Pages
|Frontier Pharma:胰臟癌症 - First-in-Class的革新認識和商業化 Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation|
|出版日期: 2015年06月01日||內容資訊: 英文 88 Pages||
Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.
A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition implies that the approach to pancreatic cancer treatment is changing and first-in-class innovation is playing a significant role in this.